Resources and Articles

• Regarding COVID-19, A Message to the NORML Family from the Executive Director
• Is Marijuana an ‘Essential’ Like Milk or Bread? Some States Say Yes
• New Mexico Ranks High in New Cannabis Study
• DOJ Memo Blocks Gun Sales to ‘Habitual Marijuana Users’
• Sacred Garden, Inc. vs. New Mexico Taxation & Revenue Department
• 2019 Cannabis Related Legislative Bill Support
• Top Four Concerns for Tri-Party Cannabis Supply Chain Agreements
• Cannabis Litigation: TCPA Claims
• Colorado: Law Explicitly Permits Banks to Loan Money to Marijuana Businesses
• Growing Forward and Looking to the Past
• The Cannabis Market Already Exists. Let's Regulate It. 
• Mexican Cannabis: Legalization is Happening! Are You Ready? 
• Petition 2019-007
• United Nations Approves WHO Recommendation to Reschedule Cannabis in Historic Vote
• House Passes Historic Bill to Decriminalize Cannabis
• House Passes Marijuana Decriminalization Bill
• Opinion: Understanding the Emergence of Climate, and Cannabis" by Terence L. Jones, PhD
• Opinion: Justice Reimagined in the Southwest: Health, Race, Cannabis, and Policing by Terence L. Jones, PhD
• Marijuana Reform: Free Allen Russell
• Cannabis Sales Near $39 million in May

Federal Register - Drug Enforcement Administration Hearing on Dec. 2

SUMMARY: This is notice that the Drug Enforcement Administration will hold a hearing with respect to the proposed rescheduling of marijuana into schedule III of the Controlled Substances Act. The proposed rescheduling of marijuana was initially proposed in a Notice of Proposed Rulemaking published in the Federal Register on May 21, 2024. DATES: Interested persons desiring to participate in this hearing must provide written notice of desired participation as set out below, on or before September 30, 2024. The hearing will commence on December 2, 2024, at 9 a.m. ET at 700 Army Navy Drive, Arlington, VA 22202. The hearing may be moved to a different place and may be continued from day to day or recessed to a later date without notice other than announcement thereof by the presiding officer at the hearing. 21 CFR 1316.53. ADDRESSES: To ensure proper handling of notification, please reference ‘‘Docket No. DEA–1362’’ on all correspondence. • Electronic notification should be sent to nprm@dea.gov. • Paper notification sent via regular or express mail should be sent to Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration; Telephone: (571) 362–3249. Email: nprm@dea.gov."

Advising the Cannabis Client
In this article, Herrick Lidstone and Kylie Santos of Burns, Figa & Will discuss the uncertain status of cannabis law in the US and the unique ethical considerations this uncertainty creates for attorneys who represent cannabis clients.  After explaining the important ethical considerations surrounding the practice of law in the cannabis industry, this article provides practical suggestions for attorneys who wish to start or continue representing the ever-growing number of cannabis clients. 

International Cannabis Bar Association
From the INCBA:
It appears that the CARES Act relief that was intended to support small business communities across the United States has excluded any business that has received any revenue from a direct marijuana business, as defined in SBA Standard Operating Procedure 50 10 5(K).

Whether it is one hour of work, or 100% of your client book, it looks like we are subject to this quasi-legislative overreach by the SBA in excluding a large swath of the US economy from much-needed economic relief. 

The above letter that was submitted to Congressional Leadership, requesting that any active SBA guidance that purports to prohibit these professionals from relief under the CARES Act be overturned.